{"id":2254,"date":"2026-06-10T14:00:00","date_gmt":"2026-06-10T17:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2254"},"modified":"2026-06-10T14:00:00","modified_gmt":"2026-06-10T17:00:00","slug":"pgrss-clinica-medicina-cir-oncologica-retroperitoneo-sarcoma-lipossarcoma-leiomiosarcoma-nefrectomia-adrenal","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-clinica-medicina-cir-oncologica-retroperitoneo-sarcoma-lipossarcoma-leiomiosarcoma-nefrectomia-adrenal\/","title":{"rendered":"PGRSS retroper: sarcoma, lipo, leiomio, nef"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de cirurgia oncol\u00f3gica retroperitoneo que reduzem PGRSS a descarte de bisturi e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de cir oncol\u00f3gica retroperitoneo<\/strong> + RPS retroperitoneal sarcoma RPS lipossarcoma 50% well-diff WDLS+dediferenciado DDLS+myxoid+pleom\u00f3rfico<\/strong> + leiomiosarcoma 25%<\/strong> + MPNST malignant peripheral nerve sheath tumor 5%<\/strong> + PEComa+SFT solitary fibrous tumor+desmopl\u00e1sico+epithelioid sarcoma raro<\/strong> + ressec\u00e7\u00e3o compartimental compartmental resection en bloc + nefrectomia + adrenalectomia + colectomia + c\u00f3lon descendente + esplenectomia<\/strong> + doxo+ifos+dacarbazina+trabectedina+eribulina+pazopanib<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (RPS + nefrectomia carcinoma rim CCR raro associado + adrenal incidentaloma) + Grupo A4 (linfa retroperitoneal + para-a\u00f3rtica + interaortocaval + il\u00edaca primitiva + raro N+ RPS) + Grupo C (Y-90 SIRT met\u00e1stase hep\u00e1tica + IORT Mobetron+Liac intraoperat\u00f3ria + brachy Iridium-192 raro) + Grupo E (perfuro bi\u00f3psia core US\/CT-guided + agulha Tru-Cut 14G+18G + bi\u00f3psia incisional aberta) + Lista C5 (doxorrubicina Adriamycin + ifosfamida Ifex + dacarbazina + trabectedina Yondelis PharmaMar + eribulina Halaven Eisai + pazopanib Votrient + regorafenib Stivarga + olaratumab Lartruvo descontinuado 2018+ + selinexor Xpovio sarcoma DDLS + ripretinib GIST). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para gaze cir\u00fargica<\/strong> + ignoram especificidades oncol\u00f3gicas + ressec\u00e7\u00e3o compartimental<\/strong> + subdimensionam Lista C5 trabectedina+eribulina<\/strong> + perdem rastreabilidade tumor retroperitoneal<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS retroperitoneo opera em 5 fluxos oncol\u00f3gicos<\/strong> \u2014 A1 (RPS lipossarcoma 50% + leiomiosarcoma 25% + MPNST 5% + outros 20%), A4 (linfadenectomia retroperitoneal seletiva + ressec\u00e7\u00e3o compartmental en bloc), C (Y-90 SIRT + IORT Mobetron + brachy raro), E (bi\u00f3psia core 14G US\/CT-guided + Tru-Cut + incisional), Lista C5 (doxo+ifos 1L sist\u00eamico + trabectedina Yondelis + eribulina Halaven + pazopanib Votrient + selinexor DDLS).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de cir oncol\u00f3gica retroperitoneo, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos oncol\u00f3gicos retroperitoneo<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o PGRSS retroperitoneo tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
A1 RPS+CCR+adrenal<\/td>\n5-13 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nLPS 50%+LMS 25%+MPNST<\/td>\n<\/tr>\n
A4 compartmental en bloc<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nNefr+adren+col+esplen<\/td>\n<\/tr>\n
C Y-90+IORT Mobetron<\/td>\n0,5-1,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nSIRT+intraoperat\u00f3ria<\/td>\n<\/tr>\n
E bi\u00f3psia core 14G<\/td>\n0,4-1,2 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nUS\/CT-guided+Tru-Cut<\/td>\n<\/tr>\n
Lista C5 doxo+trabect<\/td>\n1,5-4,5 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nYondelis+Halaven<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,4-32,2 kg\/dia<\/strong> em cl\u00ednica cir oncol\u00f3gica retroperitoneo m\u00e9dia porte.<\/p>\n

A1 RPS lipossarcoma + leiomiosarcoma + MPNST: o est\u00e1gio cir\u00fargico<\/h2>\n

A primeira camada do PGRSS retroperitoneo \u00e9 A1. Padr\u00e3o setorial inclui (a) lipossarcoma RPS 50%<\/strong> com WDLS well-differentiated 50% indolente recorr\u00eancia local + DDLS dediferenciado 25% agressivo met\u00e1stase + myxoid 15% jovem + pleom\u00f3rfico 10% alto grau + MDM2 amplification + FISH break-apart; (b) leiomiosarcoma LMS 25%<\/strong> com origem m\u00fasculo liso vascular IVC inferior vena cava + uterino + intestinal + ginecol\u00f3gico + alto grau + grade FNCLCC 2-3; (c) MPNST malignant peripheral nerve sheath tumor 5%<\/strong> com NF1 neurofibromatose tipo 1 50% + espor\u00e1dico + plexo lombar+sacral + S100+ + SOX10+ + H3K27me3 perda; (d) outros 20%<\/strong> com PEComa perivascular epithelioid + SFT solitary fibrous tumor STAT6+ + DSRCT desmoplastic small round cell + EHE epitelioide hemangioendotelioma WWTR1-CAMTA1 + sarcoma sinovial SS18-SSX + indiferenciado UPS undifferentiated pleomorphic; (e) estadiamento AJCC TNM 8\u00aa + grade FNCLCC<\/strong> Federation Nationale Centres Lutte Contre Cancer 1-3 baseado mitose+necrose+diferencia\u00e7\u00e3o + biopsia core 14G US\/CT-guided pr\u00e9-cirurgia padroniza\u00e7\u00e3o.<\/p>\n

Cl\u00ednica com A1 RPS madura garante margem R0<\/strong> + previne recidiva local<\/strong> + otimiza FNCLCC grade<\/strong>. Como discutimos no post sobre sarcoma partes moles<\/a>, A1 RPS \u00e9 base.<\/p>\n

A4 ressec\u00e7\u00e3o compartimental en bloc + nefrectomia + adrenalectomia + colectomia: o est\u00e1gio cir\u00fargico<\/h2>\n

A segunda camada \u00e9 t\u00e9cnica. Padr\u00e3o setorial inclui (a) ressec\u00e7\u00e3o compartimental compartmental resection en bloc<\/strong> com Bonvalot+Gronchi philosophy + ressec\u00e7\u00e3o em bloco \u00f3rg\u00e3os adjacentes + nefrectomia + adrenalectomia + colectomia parcial + c\u00f3lon descendente + esplenectomia + cauda p\u00e2ncreas + psoas; (b) planejamento pr\u00e9-operat\u00f3rio<\/strong> com CT trif\u00e1sico contraste + RM gadolinio + bi\u00f3psia core 14G US\/CT-guided + multidisciplinar tumor board MDT + HEP+CCV+UROL+ONCO+RT; (c) abordagem cir\u00fargica<\/strong> com laparotomia mediana xifo-pubiana + cervical incision + thoraco-abdominal incision + RPLND nerve-sparing + estadio + tipo histol\u00f3gico; (d) STRASS + STRASS-2 prospectivos<\/strong> RT preoperat\u00f3ria vs cirurgia sola + EORTC sarcoma group + recidiva local 30-50% RPS sem RT vs 10-25% com RT preop + HRT hipofracionada IORT; (e) complica\u00e7\u00e3o cir\u00fargica<\/strong> hemorragia maci\u00e7a transfus\u00e3o massiva + infec\u00e7\u00e3o s\u00edtio cir\u00fargico SSI + \u00edleo prolongado + f\u00edstula intestinal + linforr\u00e9ia + DVT+TEP + IRA insufici\u00eancia renal aguda p\u00f3s-nefrectomia.<\/p>\n

Cl\u00ednica com A4 compartmental en bloc madura escala R0 50-70%<\/strong> + previne recidiva local 10-25%<\/strong> + gerencia perda renal+adrenal+espl\u00eanica multi-\u00f3rg\u00e3o<\/strong>. Conex\u00e3o com adrenal<\/a>.<\/p>\n

Doxo+ifos 1L + trabectedina Yondelis + eribulina Halaven + pazopanib + selinexor DDLS + IORT Mobetron: o est\u00e1gio sist\u00eamico+radio<\/h2>\n

A terceira camada \u00e9 sist\u00eamico+radio. Padr\u00e3o setorial inclui (a) doxo+ifos 1L sist\u00eamico padr\u00e3o sarcoma alto grau<\/strong> doxorrubicina Adriamycin 75 mg\/m\u00b2 + ifosfamida Ifex 10 g\/m\u00b2 + Mesna+G-CSF profil\u00e1tico Neulasta + dacarbazina + EORTC 62012; (b) trabectedina Yondelis PharmaMar 2L<\/strong> 1,5 mg\/m\u00b2 IV 24h q3w + lipossarcoma+leiomiosarcoma + SARC-029+EORTC + eribulina Halaven Eisai 1,4 mg\/m\u00b2 IV D1+D8 q3w + lipossarcoma + EORTC 62091 + Sch\u00f6ffski; (c) pazopanib Votrient Novartis VEGFR\/PDGFR\/c-KIT TKI<\/strong> 800mg PO QD + STS sarcoma n\u00e3o-adipoc\u00edtico + PALETTE trial + cabozantinib + sorafenib + regorafenib Stivarga + olaratumab Lartruvo descontinuado 2018+; (d) selinexor Xpovio Karyopharm XPO1 inhibitor 2L DDLS<\/strong> dediferenciado lipossarcoma + SEAL-3 + 60mg PO 2\u00d7 weekly; (e) IORT Intraoperative Radiation Therapy<\/strong> com Mobetron Intraop Medical + Liac Sordina+SIT + 10-20 Gy intraoperat\u00f3ria dose \u00fanica + LINAC m\u00f3vel sala cir\u00fargica + braquiterapia HDR Iridium-192 raro + EBRT preop 50-50,4 Gy + STRASS RT preoperat\u00f3ria + Lista C5 + CNEN-NN-3.05.<\/p>\n

Cl\u00ednica com doxo+ifos+trabectedina+IORT madura escala OS RPS 5y 50-70% R0 + grade 1-2<\/strong> + escala trabectedina+eribulina PFS 4-7m 2L<\/strong> + escala IORT recidiva local -30-50%<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por capacidade retroperitoneo<\/h2>\n

Cl\u00ednica retroperitoneo s\u00f3 A1.<\/strong> 1 fluxo. Custo mensal R$ 9.000-26.000<\/strong> mas perda de A4+C+E+sist\u00eamico.<\/p>\n

Cl\u00ednica retroperitoneo A1 + A4 + doxo+ifos.<\/strong> 3 fluxos. Custo mensal R$ 22.000-54.000<\/strong>, captura cirurgia + sist\u00eamico padr\u00e3o.<\/p>\n

Cl\u00ednica retroperitoneo 5 fluxos completos.<\/strong> A1+A4+C+E+sist\u00eamico + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 40.000-95.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura completa retroperitoneo + R0 50-70% + IORT recidiva -30-50%.<\/p>\n

Os tr\u00eas erros que aparecem em cir oncol\u00f3gica retroperitoneo<\/h2>\n

O primeiro \u00e9 a subdimensionamento Lista C5 sarcoma<\/strong>. Sem segrega\u00e7\u00e3o doxo+ifos+dacarbazina+trabectedina+eribulina+pazopanib+selinexor+regorafenib + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura A1 lipossarcoma + leiomiosarcoma + MPNST<\/strong>. Confunde rastreabilidade tipo histol\u00f3gico + impossibilita FNCLCC grade 1-3 + risco indica\u00e7\u00e3o inadequada (DDLS selinexor vs LMS trabectedina vs lipo eribulina).<\/p>\n

O terceiro \u00e9 a falta de protocolo MDT tumor board pr\u00e9-cirurgia<\/strong>. Sem CT trif\u00e1sico+RM gadolinio + bi\u00f3psia core 14G pr\u00e9 + tumor board multidisciplinar + STRASS RT preop = perda planejamento + zero R0 padroniza\u00e7\u00e3o + risco recidiva local 30-50% sem RT preop.<\/p>\n

A regula\u00e7\u00e3o de PGRSS retroperitoneo no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com cir oncol\u00f3gica preservadora como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com PGRSS cl\u00ednicas especializadas<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A INCA C\u00e2ncer Sarcoma<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS retroperitoneo 5 fluxos oncol\u00f3gicos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a A1 RPS lipossarcoma 50% WDLS well-diff+DDLS dediferenciado+myxoid+pleom\u00f3rfico+MDM2 amplification+FISH break-apart+leiomiosarcoma 25% IVC inferior vena cava+uterino+grade FNCLCC 2-3+MPNST 5% NF1+espor\u00e1dico+plexo+S100+SOX10+H3K27me3 perda+PEComa+SFT STAT6+DSRCT+EHE WWTR1-CAMTA1+sarcoma sinovial SS18-SSX+UPS+AJCC TNM 8\u00aa+CID C48, A4 ressec\u00e7\u00e3o compartimental compartmental en bloc Bonvalot+Gronchi philosophy+nefrectomia+adrenalectomia+colectomia parcial+c\u00f3lon descendente+esplenectomia+cauda p\u00e2ncreas+psoas+CT trif\u00e1sico+RM gadolinio+MDT tumor board+STRASS-2 RT preoperat\u00f3ria EORTC+IORT hipofracionada+complica\u00e7\u00e3o SSI+\u00edleo+f\u00edstula+linforr\u00e9ia+IRA, C Y-90 SIR-Spheres+TheraSphere met\u00e1stase hep\u00e1tica+IORT Mobetron Intraop Medical+Liac Sordina+SIT 10-20 Gy intraoperat\u00f3ria+Iridium-192 brachy raro+CNEN-NN-3.05, E bi\u00f3psia core 14G US\/CT-guided+Tru-Cut+aberta incisional+Mohs intraoperat\u00f3ria freezing, sist\u00eamico doxo Adriamycin+ifos Ifex+Mesna+Neulasta G-CSF+EORTC 62012+trabectedina Yondelis PharmaMar SARC-029+EORTC+eribulina Halaven Eisai EORTC 62091 Sch\u00f6ffski+pazopanib Votrient Novartis PALETTE+selinexor Xpovio Karyopharm XPO1 SEAL-3 DDLS+regorafenib Stivarga Lista C5.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS oncologia retroperitoneo: sarcoma + lipo + leiomio + nef. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2253,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2712,3089,3088,2992],"class_list":["post-2254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cirurgia-oncologica","tag-lipossarcoma","tag-retroperitoneo","tag-sarcoma"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2254"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2254\/revisions"}],"predecessor-version":[{"id":4350,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2254\/revisions\/4350"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2253"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}